Background: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease affecting 0.5% of Spanish population. This disease results in a significant radiological and functional deterioration, decreasing the quality of life and increasing its mortality if an specific treatment is not applied. Although the radiological and functional deterioration progress slowly during the whole course of the disease, it has been proven that early and aggressive approach to the disease is important in order for its control because the final outcome can be improved with a close, intense and early follow-up. Objectives: To describe the clinical characteristics and evolution during 5 years of disease activity in RA patients derived from a recent arthritis clinic. Methods: A prospective longitudinal study was carried out of 154 patients diagnosed from 2003 to 2012. They included patients over 18 years old diagnosed with RA (ACR criteria 1987) and with 5 years of follow-up. Socio-demographic and clinical variables such as Rheumatoid factor (FR) and anti-citrullinated peptide antibodies (ACPA) or disease activity (DAS28-VSG) as well as treatment were assessed in those patients. Mean and standard deviation of quantitative variables and frequencies and percentages of qualitative variables were calculated. Proportions were compared using the Cochran Q test statistic in order to compare differences between remission (determined by DAS-28 <2.6) measured at 1 year, 2 years and 5 years from diagnosis. Data were analyzed using SPSS v17 program. Results: Of the 154 patients, 66.2% were females with a mean age at diagnosis of 52.88±14.64 years. Only 18.8% (29) patients were smokers; 67.5% (104) of patients were RF positive and 57% (88) of them were ACPA positive. Clinical remission measured by means of DAS 28-VSG (<2.6) was achieved in 84 patients (54.5%), 92 patients (59.7%) and 95 patients (61.7%) after 1, 2 and 5 years, respectively. Mean values of DAS 28 were 2.58 (2.02) at first year, 2.56 (1.99) at two years and 2.59 (2.02) at 5 years. Of the 154 patients, 108 (78.8%) started treatment with monotherapy (mostly methotrexate) and after 5 years only 18 (25.7%) patients were on biological treatment. No differences were found when remission was compared at first, second and 5 years of follow-up. Subsequent comparison of two-to-two ratios among the three groups using χ 2 contrast also indicated that there were no statistically significant differences between groups. However a tendency in data was observed, so that once patients had reached the remission at first year there was no increase in the number of them showing remission in the successive years of follow-up. Conclusions: These results suggest that achieving an early control of the disease is of importance, since control of the disease becomes more difficult as the delay of the diagnosis increases. Background: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has proven clinical benefits, however objective adherence T2T measurement tools are lacked in daily practice. Objectives: To evaluate the setting, usage of a T2T adherence measure: T2T70 and T2T100, and its association with sustained low disease activity (LDAS) as a measure of outcome. Methods: Prospective study, consecutive patients with RA diagnosis (ACR/EULAR 2010) and follow-up between 1 and 24 months were included. Data from electronic medical record (EHR) were collected. Demographic variables, characteristics of the disease and treatment were recorded. The following T2T characteristics were defined and collected from each patient: number of visits, visits where treatment was adjusted, CDAI measurements, use of ultrasound to measure disease activity and achievement of LDA. Sustained LDA (LDAS) was defined when the patient had 2 or more records of that consecutive state of activity. Measures of adherence to T2T were defined as follows: T2T-70, when therapeutic decisions were accompanied by the measurement of activity by 70% and the interval between visits did not exceed 6 months; And T2T-100, when 100% of the decisions were accompanied with the activity measurement and the interval between each visit did not exceed 6 months. Statistical analysis: a
contrast also indicated that there were no statistically significant differences between groups. However a tendency in data was observed, so that once patients had reached the remission at first year there was no increase in the number of them showing remission in the successive years of follow-up. Conclusions: These results suggest that achieving an early control of the disease is of importance, since control of the disease becomes more difficult as the delay of the diagnosis increases. Background: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has proven clinical benefits, however objective adherence T2T measurement tools are lacked in daily practice. Objectives: To evaluate the setting, usage of a T2T adherence measure: T2T70 and T2T100, and its association with sustained low disease activity (LDAS) as a measure of outcome. Methods: Prospective study, consecutive patients with RA diagnosis (ACR/EULAR 2010) and follow-up between 1 and 24 months were included. Data from electronic medical record (EHR) were collected. Demographic variables, characteristics of the disease and treatment were recorded. The following T2T characteristics were defined and collected from each patient: number of visits, visits where treatment was adjusted, CDAI measurements, use of ultrasound to measure disease activity and achievement of LDA. Sustained LDA (LDAS) was defined when the patient had 2 or more records of that consecutive state of activity. Measures of adherence to T2T were defined as follows: T2T-70, when therapeutic decisions were accompanied by the measurement of activity by 70% and the interval between visits did not exceed 6 months; And T2T-100, when 100% of the decisions were accompanied with the activity measurement and the interval between each visit did not exceed 6 months. Statistical analysis: a descriptive analysis of the variables was performed and Chi2 test (categorical) and Student or MannWhitney test (continuous) were applied. For multivariate logistic regression analysis we considered as dependent variable LDAs. Results: 96 patients were included, with a mean follow-up of 15 months (DS 7.8), equivalent to 120.6 patients/year. Eighty percent of the patients were women, mean age 53.7 years (SD 13), disease duration 36 months (RIC, 12-52), 64% had early diagnosis, 85% and 75% positive For FR and ACPA, respectively. According to T2T characteristics, 526 visits were recorded, 270 were treatment adjustment and 208 (78%) of them were performed according to the CDAI value. The frequency of LDAS was 20% (IC95: 12-30). The frequency of T2T-70 compliance was 62.5% (IC95: 52-72) and T2T-100 was 42% (IC95: 32-52). Compliance with T2T-70 and T2T-100 presented a statistically significant association to the achievement of LDAS in the uni and multivariate analysis (p: 0.000). Compliance with T2T-70 and T2T-100 was associated with a shorter time course of disease; And T2T-70 also showed association with early diagnosis. Conclusions: T2T-70 and T2T-100 adherence were 62% and 42%, respectively, patients who met these criteria reached more LDAS. The early diagnosis and shorter time to disease evolution at baseline were variables that were variables that were associated with more compliance of these tools. Acknowledgements: Dra Josefina Marcos. Background: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are associated with a significant benefit in long-term disease outcome. Objectives: Our objective was to determine the proportion of patients with newly diagnosed RA in whom first rheumatology assessment and/or initiation of DMARD therapy was within the desired time frame. Methods: A retrospective chart review of adult patients diagnosed with RA during years 2014 and 2015 was performed at the rheumatology department of an integrated secondary/tertiary teaching hospital that provides rheumatology services for a population of more than 500.000 residents. Potential cases were identified by searching the electronic medical records for ICD-10 codes M05.* and M06.* Electronic and paper records of patients were then thoroughly reviewed. In addition to demographic and clinical data, dates were recorded for onset of inflammatory joint symptoms, referral to rheumatologist, initial assessment by a rheumatologist and initiation of DMARD therapy. The percentage of patients assessed by a rheumatologist and/or treated with a DMARD within 12 weeks of symptom onset and the median times for delay were then calculated. Results: Between January 1st 2014 and December 31st 2015, 243 new cases of RA were identified at our Department of Rheumatology. Of those, 197 (81.1%) were referred to our early interventional clinic. Within 12 weeks of symptom onset, 111 (45.7%) new RA patients were examined by a rheumatologist and 87 (35.8%) were started on DMARD therapy; the median time from symptom onset to consultation was 13.0 (IQR 4.6-27.8) weeks, median time from referral to consultation was 1 (IQR 1-3) days and median DMARD treatment delay was 15.7 (IQR 8.7-31.9) weeks. 0.14 (IQR, 0.14-0.43) Time from symptom onset to glucocorticoid initiation, weeks (median) 13.1 (IQR, 5.6-26.9) Time from symptom onset to DMARD initiation, weeks (median) 15.7 (IQR, Conclusions: 46% of new RA patients were assessed by a rheumatologist and 36% were treated with a DMARD within the recommended time frame of 12 weeks. Most of the treatment delay was due to the time elapsed between symptom onset and referral to a rheumatologist. These results substantiate the efficacy of our early interventional clinic in diagnosing and treating patients with early RA: despite the heavily protracted nationwide waiting times for first rheumatologist assessment and significantly (40%) lower number of rheumatologists per capita compared to European Union average, the percentage of timely treated patients was comparable to recent reports. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5276
